MototsuguTanaka NiigataJapan

• Clinical impacts and importance of minimizing drug approval delay (include approval process in US/Europe)
  NaokiKashihara Speaker kashinao@med.kawasaki-m.ac.jpJapan
• HCE (hierarchical composite end points) and eGFR slope, as potential solutions to delays in approval
  HiddoLambers Heerspink Speaker H.J.Lambers.Heerspink@umcg.nlNetherlands
• Bridging Academia and Regulators in Kidney Drug Development: Insights from Japan
  MototsuguTanaka Speaker mototsugu.tanaka@gmail.comJapan
• Panel Discussion
  HiddoLambers Heerspink Speaker H.J.Lambers.Heerspink@umcg.nlNetherlands

  MototsuguTanaka Speaker mototsugu.tanaka@gmail.comJapan

  NaokiKashihara Speaker kashinao@med.kawasaki-m.ac.jpJapan